| abstract |
1. The composition of the prodrug, comprising at least one conjugate of methylphenidate, where the conjugate has the following structure: where A for each repeating subgroup is independently selected from the group consisting of CRR, aryl group, substituted aryl group, arylene, carbocycle, cycloalkenyl group, cycloalkyl group , cycloalkynyl group, heterocycle and heteroaryl group; where R and R are selected independently of each other and independently for each repeating subgroup of the group consisting of hydrogen, alkenyl group, alkenylamine carbonyl group, alkoxy group, alkoxycarbonyl group, alkyl group, alkylamino group, alkylaminocarbonyl group, alkylammonium group, alkylcarbonyl group, alkylcarbonylamino group, alkylcarbonyloxy group, alkylsulfinyl group, alkylsulfonyl group, alkylthio group, alkynylamino, aminoalkylamino, aminonamino, amino a substituted aryl group, an arylalkenyl group, an arylalkoxy group, an arylalkyl group, an arylalkynyl group , Arylamino, arylaminocarbonyl, arylammonium, arilazogruppy, arylcarbonyl groups, arylcarbonylamino, arylcarbonyloxy, arylcycloalkyl group, aryloxy group, aryloxyalkyl group, arylsulfonyl group, arilsulfinilalkilnoy group, an arylsulfonyl group, arylsulfonylamino group, arylthio group, ariltioalkilnoy group, a cyano group, a cycloalkenyl group tsikloalkenilalkilnoy group, a carboxyl groups, cycloalkyl groups, cycloalkylalkyl groups, cycloalkylamino |